ANTI-COV-2: COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2
Study Details
Study Description
Brief Summary
Rationale : The emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) threatens public health. To date, there are no effective drug option to prevent the infection, nor therapeutics for controlling the deadly COVID-19. However, the majority of patients infected with SARS-Cov-2 eliminate the virus by mounting a protective antiviral immune response, associated in particular with the production of neutralizing antibodies. Neutralizing antibodies could be of particular interest for therapeutic purposes, but also for preventive applications, to protect people who have never been in contact with the virus, or immunocompromised patients.
The objectives of this study are :
-
To generate human monoclonal antibodies neutralizing SARS-Cov-2 from immortalized B cells of convalescent patients.
-
To compare the serological profiles between convalescent patients that develop mild or uncomplicated illness and convalescent patients that develop a more severe disease, that required hospitalization and oxygen support.
-
To compare for each patient the neutralizing efficiency of plasma to the neutralizing capacities of the monoclonal antibodies generated with immortalized B cells.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Convalescent patients diagnosed with COVID + Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID + on the temporary sampling platform that was set up at HCL at the start of the epidemic, which notably concerns symptomatic healthcare professionals for whom hospitalization does not was not necessary. |
Other: Blood sample
This study will require a blood sample (4 ACD tubes, 20 ml) at one time.
|
| Hospitalized convalescent patients diagnosed with COVID + Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID +, hospitalized in the infectious diseases department of the Croix-Rousse hospital living in the metropolitan area of Lyon, having presented hypoxaemic pneumonia requiring hospitalization. |
Other: Blood sample
This study will require a blood sample (4 ACD tubes, 20 ml) at one time.
|
Outcome Measures
Primary Outcome Measures
- Production of several human monoclonal antibodies capable of neutralizing the infection of a target cell by SARS-COV-2. [3 weeks]
Isolation of immortalized B lymphocyte clones, producer of monoclonal antibodies capable of neutralizing the infection of a target cell by SARS-COV-2.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient over 18 years old
-
Patient who signed the study consent form
-
Convalescent patient (at least 12 days after the onset of symptoms), having been sampled at Hospices Civils de Lyon for a suspected infection with SARS-Cov-2, confirmed by PCR.
Exclusion Criteria:
-
Patient treated with rituximab
-
Patient treated with immunoglobulins
-
Patient over 18 years old, subject to a legal protection measure (guardianship or trusteeship)
-
Patient deprived of liberty
-
Pregnant or lactating woman
-
Patient not affiliated to a social security scheme or beneficiary of a similar scheme.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hôpital de la Croix-Rousse | Lyon | France |
Sponsors and Collaborators
- Hospices Civils de Lyon
- Eurobio Scientific
Investigators
- Principal Investigator: Frédéric COUTANT, MD, Hospices Civils de Lyon
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 69HCL20_0340
- 2020-A01038-31